Omalizumab for the treatment of severe allergic asthma

References

• Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy59(5), 469–478 (2004).
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Takeda K. Role of IgE in the development of allergic airways inflammation and airways hyperresponsiveness – a murine model. Allergy54, 297–305 (1999).
   PubMed Web of Science ®Google Scholar
• Sunyer J, Anto JM. Relationship between serum IgE and airway responsiveness in adults with asthma. J. Allergy Clin. Immunol.95, 699–706 (1995).
   PubMed Web of Science ®Google Scholar
• Heaney LH, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet365, 974–976 (2005).
   PubMed Web of Science ®Google Scholar
• Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations and unanswered questions. Am. J. Respir. Crit. Care Med.162, 2341–2351 (2000).
   PubMedGoogle Scholar
• Robinson DS, Campbell DA. Systematic assessment of difficult-to-treat asthma. Eur. Respir. J.22, 478–483 (2003).
   PubMed Web of Science ®Google Scholar
• Moore WC, Bleecker ER, Curran-Everett D et al. Characterization of the severe asthma phenotype by the National Heart, Lung and Blood Institute’s Severe Asthma Research Program. J. Allergy Clin. Immunol.119, 405–413 (2007).
   PubMed Web of Science ®Google Scholar
• Pollart SM, Chapman MD, Fiocc GP, Rose G, Platts-Mills TA. Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J. Allergy Clin. Immunol.83, 875–882 (1989).
   PubMed Web of Science ®Google Scholar
• Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N. Engl. J. Med.325, 1067–1071 (1991).
   PubMed Web of Science ®Google Scholar
• Peat JK, Toelle BG, Dermand J, Van Den BR, Britton WJ, Woolcock AJ. Serum IgE levels, atopy and asthma in young adults: results from a longitudinal cohort study. Allergy51, 804–810 (1996).
   PubMed Web of Science ®Google Scholar
• Presta LG, Lahr SJ, Shields RL. Humanization of an antibody directed against IgE. J. Immunol.15, 2623–2632 (1993).
   Google Scholar
• Djukanovic R, Wilson SJ, Kraft M et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med.170, 583–593 (2004).
   PubMed Web of Science ®Google Scholar
• Corne J, Djukanovic R, Thomas L. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety and pharmacokinetics. J. Clin. Invest.99, 879–887 (1997).
   PubMed Web of Science ®Google Scholar
• Fahy JV, Fleming HE. The effect of an anti-IgE monoclonal antibody on the early and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med.155, 1828–1834 (1997).
   PubMed Web of Science ®Google Scholar
• Milgrom H, Fick RB. Treatment of allergic asthma with monoclonal anti-IgE antibody. N. Engl. J. Med.341, 1966–1973 (1999).
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J.18, 254–261 (2001).
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J. Omalizumab, anti-IgE recombinant humanised monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol.108, 184–190 (2001).
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy59, 701–708 (2004).
   PubMed Web of Science ®Google Scholar
• Holgate S, Chuchalin AG, Hebert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy34, 632–638 (2004).
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy60, 309–316 (2005).
   PubMed Web of Science ®Google Scholar
• Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev.91, CD003559 (2006).
   Google Scholar
• Holgate S, Bosquet J, Wenzel S, Fox H, Kiu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr. Med. Res. Opin.17, 233–240 (2001).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy60, 302–308 (2005).
   PubMed Web of Science ®Google Scholar
• Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy62, 149–153 (2007).
   PubMed Web of Science ®Google Scholar
• Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost–effectiveness of omalizumab in adults with severe asthma: results from the asthma policy model. J. Allergy Clin. Immunol.120, 1146–1152 (2007).
   PubMed Web of Science ®Google Scholar
• Chipps B, Buhl R, Beeh KM, Fox H, Thomas K, Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr. Med. Res. Opin.22, 2201–2208 (2006).
   PubMed Web of Science ®Google Scholar
• Niebauer K, Dewilde S, Fox-Rushby J, Revicki DA. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann. Allergy Asthma Immunol.96, 316–326 (2006).
   PubMed Web of Science ®Google Scholar
• Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxis. J. Allergy Clin. Immunol.120(6), 1373–1377 (2007).
   PubMed Web of Science ®Google Scholar